<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147234</url>
  </required_header>
  <id_info>
    <org_study_id>1426-0001</org_study_id>
    <secondary_id>2019-001082-32</secondary_id>
    <nct_id>NCT04147234</nct_id>
  </id_info>
  <brief_title>A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)</brief_title>
  <official_title>Phase I, First in Human Trial Evaluating BI 1387446 Alone and in Combination With Ezabenlimab (BI 754091) in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in adults with advanced cancer (solid tumours) in whom previous treatment was&#xD;
      not successful. The study tests 2 medicines called BI 1387446 and BI 754091. Both medicines&#xD;
      may help the immune system fight cancer. In this study, BI 1387446 is given to humans for the&#xD;
      first time.&#xD;
&#xD;
      The purpose of this study is to find out the highest dose of BI 1387446 alone and in&#xD;
      combination with BI 754091 the participants can tolerate. BI 1387446 is injected directly&#xD;
      into the tumour.&#xD;
&#xD;
      Participants get BI 1387446 injections every week at the beginning and then every 3 weeks.&#xD;
&#xD;
      Some participants get BI 754091 in addition to BI 1387446. BI 754091 is given as an infusion&#xD;
      into a vein every 3 weeks.&#xD;
&#xD;
      As long as they benefit from treatment and can tolerate it, participants can stay in the&#xD;
      study for up to 2 years and 8 months. During this time, they visit the study site regularly.&#xD;
      At these visit, doctors record any unwanted effects. The doctors also regularly check&#xD;
      participants' health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">January 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) based on number of Dose-limiting toxicities (DLTs)</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with Dose limiting Toxicity (DLT) in the Maximum tolerated dose (MTD) evaluation period</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>An average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best percentage change from baseline in size of injected target lesions</measure>
    <time_frame>An average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best percentage change from baseline in size of non-injected target lesions</measure>
    <time_frame>An average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A: BI 1387446</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>superficial lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: BI 1387446 in combination with ezabenlimab (BI 754091)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>superficial lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: BI 1387446 in combination with ezabenlimab (BI 754091)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>deep lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1387446</intervention_name>
    <description>intratumoral injection</description>
    <arm_group_label>Arm A: BI 1387446</arm_group_label>
    <arm_group_label>Arm B: BI 1387446 in combination with ezabenlimab (BI 754091)</arm_group_label>
    <arm_group_label>Arm C: BI 1387446 in combination with ezabenlimab (BI 754091)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754091</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Arm B: BI 1387446 in combination with ezabenlimab (BI 754091)</arm_group_label>
    <arm_group_label>Arm C: BI 1387446 in combination with ezabenlimab (BI 754091)</arm_group_label>
    <other_name>ezabenlimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of an advanced, unresectable&#xD;
             and/or metastatic malignant solid tumor and indication for treatment&#xD;
&#xD;
          -  Patient must have exhausted established treatment options known to prolong survival&#xD;
             for the malignant disease, or is not eligible for established treatment options.&#xD;
&#xD;
          -  Medically fit and willing to undergo all mandatory trial procedures.&#xD;
&#xD;
          -  At least one tumor lesion which is suitable for injection (Screening/initial&#xD;
             administration), appropriate for the allocated treatment arm, and measurable.&#xD;
&#xD;
          -  At least 1 discrete lesion, in addition to the lesion proposed for injection, which is&#xD;
             amenable to biopsy and is not located in the brain, mediastinum or pancreas.&#xD;
&#xD;
          -  Adequate organ function or bone marrow reserve&#xD;
&#xD;
          -  Further inclusion criteria apply&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any investigational or antitumour treatment (including antibodies targeting Programmed&#xD;
             Cell Death-1 (PD1) - or programmed Death-Ligand 1 (PDL1)) within 4 weeks or 5&#xD;
             half-life periods (whichever is shorter) prior to the initial administration of BI&#xD;
             1387446 or BI 754091.&#xD;
&#xD;
          -  Persistent toxicity from previous treatments (including Immune-related Adverse Events&#xD;
             (irAEs)) that has not resolved to ≤ Grade 1, except for alopecia, xerostomia, and&#xD;
             immunotherapy related endocrinopathies which may be included if clinically stable on&#xD;
             hormone supplements or antidiabetic drugs as per Investigator judgement&#xD;
&#xD;
          -  History or evidence of active, non-treatment related autoimmune disease, except for&#xD;
             endocrinopathies which may be included if clinically stable on hormone supplements or&#xD;
             antidiabetic drugs.&#xD;
&#xD;
          -  History or evidence of pneumonitis related to prior immunotherapy&#xD;
&#xD;
          -  Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within&#xD;
             2 weeks prior to the first dose of BI 1387446 or BI 754091.&#xD;
&#xD;
          -  The tumor at the projected injection site has a high risk for local complications,&#xD;
             e.g. bleeding related to encasement/infiltration of major blood vessels or contact&#xD;
             with liver capsule, compression of vital structures in case of swelling of injected&#xD;
             lesion, in the opinion of the Investigator.&#xD;
&#xD;
          -  Active infection requiring systemic therapy at the start of treatment in the trial,&#xD;
             including active viral hepatitis infection or active tuberculosis infection.&#xD;
&#xD;
          -  Cardiac insufficiency New York Heart Association (NYHA) III or IV&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50% measured by echocardiography or Multigated&#xD;
             Acquisition (MUGA) scan&#xD;
&#xD;
          -  Mean resting corrected QT interval (QTc) &gt;470 msec&#xD;
&#xD;
          -  Arm C: Patients on therapeutic doses of anticoagulants.&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center-New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Ingham</last_name>
      <phone>+001(646)317-7141</phone>
      <email>mi2337@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Weiss</last_name>
      <phone>+001(919)843-7718</phone>
      <email>jared_weiss@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert and The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Thompson</last_name>
      <phone>+001(414)805-4600</phone>
      <email>jrthomps@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garralda</last_name>
      <phone>+34932746085</phone>
      <email>egarralda@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIO Clara Campal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano Calvo</last_name>
      <phone>+34902107469</phone>
      <email>emiliano.calvo@startmadrid.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Manuel Cervantes Ruiperez</last_name>
      <phone>+34961973527</phone>
      <email>andres.cervantes@uv.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Harrington</last_name>
      <phone>02071535157</phone>
      <email>kevin.harrington@icr.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Parkes</last_name>
      <phone>01865741841</phone>
      <email>eileen.parkes@oncology.ox.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Harrington</last_name>
      <phone>02071535157</phone>
      <email>kevin.harrington@icr.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

